Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CABATEN trial: what clinicians have said so far
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
- NCT04400474 ↗
- Completed
- Grupo Espanol de Tumores Neuroendocrinos
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on CABATEN (cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CABATEN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 16 posts on X | |
| 2 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Neuroendocrine Tumor; Anaplastic Thyroid Cancer; Adenocarcinoma; Pheochromocytoma; Paraganglioma
- Interventions
- Cabozantinib 40 mg
- Arms
- Cabozantinib 40 mg + Atezolizumab 1200 mg · Experimental
- Enrollment
- 93
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos with Ipsen, Roche Pharma AG
- Start
- Oct 7, 2020
- Primary completion
- Nov 23, 2023
- Results posted
- Yes
- Registry record
- NCT04400474 · updated Jun 19, 2025